Table 1.
Patient characteristics at index decompensation in the overall cohort (n = 622).
| Value | |
|---|---|
| Patients, n (%) | 622 (100%) |
| Age (years), mean ± SD | 56.5 ± 11.2 |
| Sex (male), n (%) | 423 (68%) |
| Aetiology∗, n (%) | |
| Alcohol-related liver disease | 366 (59%) |
| HCV | 142 (23%) |
| HBV | 58 (9%) |
| NAFLD | 75 (12%) |
| Autoimmune | 30 (5%) |
| Other | 36 (6%) |
| Ascites grade, n (%) | |
| Grade 2/moderate | 323 (52%) |
| Grade 3/severe | 299 (48%) |
| Varices† (yes vs. no), n (%) | |
| None | 193 (31%) |
| Small | 198 (32%) |
| Large | 204 (33%) |
| Child–Pugh stage, n (%) | |
| A | 93 (15%) |
| B | 359 (58%) |
| C | 170 (27%) |
| Child–Pugh score, median (IQR) | 8 (7–9) |
| MELD, mean ± SD | 15.1 ± 5.9 |
| Non-selective beta-blocker, n (%) | 224 (36%) |
| Diuretics, n (%) | 554 (89%) |
| Furosemide | 53 (9%) |
| Anti-aldosteronic | 125 (20%) |
| Both | 376 (61%) |
| Albumin (g/L), mean ± SD | 32.2 ± 6.1 |
| Bilirubin (mg/dl), median (IQR) | 1.96 (1.10–3.55) |
| INR, mean ± SD | 1.42 ± 0.32 |
| Platelets (g/L), median (IQR) | 114 (72–164) |
INR, international normalised ratio; MELD, model for end-stage liver disease; NAFLD, non-alcoholic fatty liver disease.
∗
Patients may have more than 1 liver disease aetiology.
†
Missing information in 27 (4%) patients.